Literature DB >> 1700945

Pneumothorax following cytotoxic chemotherapy in malignant lymphoma.

J R Hsu1, S C Chang, R P Perng.   

Abstract

Pneumothorax occurring as a complication of the antitumor effect of cytotoxic chemotherapy has been reported in occasional cases of a variety of tumors. Its occurrence in malignant lymphoma has not been reported heretofore. In this report, we describe two cases of this complication in patients with malignant lymphoma and discuss the possible pathophysiologic mechanisms involved. Because pulmonary involvement with the tumor was found in both cases, pneumothorax could be attributed to the anti-tumor effect of cytotoxic agents on underlying lung involvement in patients with malignant lymphoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1700945     DOI: 10.1378/chest.98.6.1512

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

1.  Pneumothorax as an adverse drug event: an exploratory aggregate analysis of the US FDA AERS database including a confounding by indication analysis inspired by Cornfield's condition.

Authors:  Manfred Hauben; Eric Y Hung
Journal:  Int J Med Sci       Date:  2013-06-13       Impact factor: 3.738

2.  Simultaneous bilateral spontaneous pneumothorax as the first manifestation of primary pulmonary MALT lymphoma.

Authors:  Asma Migaou; Nader Slama; Manel Njima; Asma Achour; Ahmed Ben Saad; Sarra Boukhris; Nesrine Fahem; Sabrine Dimassi; Adnene Laatiri; Saoussen Cheikh Mhammed; Naceur Rouatbi; Sameh Joobeur
Journal:  Pan Afr Med J       Date:  2020-09-03

3.  Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report.

Authors:  Linda Sakhri; Elodie Meynet; Léonie Ferrer; Augustin Pirvu; Gilbert Ferretti; Denis Moro-Sibilot
Journal:  J Med Case Rep       Date:  2014-10-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.